Cenerimod matching placebo
Sponsors
Viatris Innovation GmbH
Conditions
Moderate to severe systemic lupus erythematosus
Phase 3
OPUS-1 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy
RecruitingCTIS2024-515870-28-00
Start: 2024-10-22Target: 100Updated: 2026-01-26
OPUS-2 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy
Active, not recruitingCTIS2024-515871-37-00
Start: 2024-10-24Target: 92Updated: 2025-12-14